U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07430319) titled 'Real-Life Evaluation of Guselkumab Dosing Interval Adjustments' on Feb. 18.
Brief Summary: "Guselkumab (Tremfya(R)) is a fully human monoclonal antibody that selectively targets interleukin-23 (IL-23), a key cytokine involved in the inflammatory pathways of psoriasis. This biologic therapy received marketing authorization in France in 2018 for the treatment of moderate-to-severe plaque psoriasis in adults requiring systemic therapy. This indication includes patients with extensive disease, with or without significant psychosocial impact, and those who have had an inadequate response, contraindication, or intolerance to at least two ...